Abstract P5-02-44: Efficacy analysis of CDK4/6 inhibitors in combination with endocrine therapy treatment in HR+/HER2- breast cancer according to PAM50 intrinsic subtype: primary results of SOLTI-1801_CDK-PREDICT study
Pablo Tolosa(Research Institute Hospital 12 de Octubre), Eva Ciruelos(Hospital Universitario 12 De Octubre), Fara Brasó‐Maristany(Hospital Clínic de Barcelona), Manuel Alva(Hospital Universitario 12 De Octubre), Guillermo Villacampa(Vall d'Hebron Institut de Recerca), Cristina Hernándo(Hospital Clínico Universitario de Valencia), Tomás Pascual(Breast Cancer Research Foundation), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Jordi Canes, María Rocío Moreno-Villa(Research Institute Hospital 12 de Octubre), Lucía Parrilla, Fernando Salvador(Solti), Ana María Roncero(Hospital Universitario Fundación Jiménez Díaz), Sonia Servitja(Hospital Del Mar), Adela Muñoz Fernández(Universidad de Alcalá), Aleix Prat(Hospital Clínic de Barcelona), Laura Lema(Hospital Universitario 12 De Octubre), J. Benitez(Hospital Clínico San Carlos), Yolanda Ruano(Hospital Virgen de la Salud)
Cited by 0
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k